Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.

We studied the effects of PTH on the expression of tumor necrosis factor-related activation-induced cytokine (TRANCE), osteoprotegerin (OPG), and receptor activator of NF κB (RANK) messenger RNA (mRNA) in cultured murine bone marrow, calvaria, and osteoblasts. TRANCE, OPG, and RANK are recently identified regulators of osteoclast formation. Bone marrow cells were cultured with or without PTH(1–34) for 6 days. TRANCE, OPG, and RANK mRNA were measured by RT-PCR. In 6-day cultures, PTH stimulated the number of OCL/well in a dose-dependent manner. A time course showed significant (P < 0.01) increases in OCL/well after 24 h of PTH (100 ng/ml). TRANCE mRNA expression, like OCL formation, increased dose dependently and was maximal, with 10–100 ng/ml PTH. In contrast, OPG mRNA expression was decreased by 0.1 ng/ml PTH (40%) and completely abolished by 1 ng/ml. TRANCE mRNA expression was rapidly stimulated by PTH (maximal response at 1 h, 8.1-fold over control). Expression declined by 40% at 24 h but was still muc...

[1]  T. Martin,et al.  Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. , 1998, Endocrinology.

[2]  T. Martin,et al.  A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. , 1998, Endocrinology.

[3]  Yongwon Choi,et al.  TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts , 1998, The Journal of experimental medicine.

[4]  K. Sjögren,et al.  Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. , 1998, Biochemical and biophysical research communications.

[5]  H. Yasuda,et al.  Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis. , 1998, Gene.

[6]  C. Ohlsson,et al.  Tumor Necrosis Factor-α and -β Upregulate the Levels of Osteoprotegerin mRNA in Human Osteosarcoma MG-63 Cells , 1998 .

[7]  K Yano,et al.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.

[8]  C. Ohlsson,et al.  Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. , 1998, Biochemical and biophysical research communications.

[9]  H. Yasuda,et al.  Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. , 1998, European journal of biochemistry.

[10]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[11]  N. Udagawa,et al.  Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. , 1998, Biochemical and biophysical research communications.

[12]  N. Udagawa,et al.  Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. , 1998, Biochemical and biophysical research communications.

[13]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[14]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[15]  S. Mochizuki,et al.  Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. , 1998, Biochemical and biophysical research communications.

[16]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[18]  M. Goto,et al.  Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor* , 1998, The Journal of Biological Chemistry.

[19]  K. Miyake,et al.  Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. , 1998, Biochemical and biophysical research communications.

[20]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[21]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[22]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[23]  S. Mochizuki,et al.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.

[24]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[25]  J. Kalinowski,et al.  Interleukin‐6 expression and histomorphometry of bones from mice deficient in receptors for interleukin‐1 or tumor necrosis factor , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  Roodman Gd.  Advances in bone biology: the osteoclast. , 1996, Endocrine reviews.

[27]  S. Goldring,et al.  Expression of the calcitonin receptor in bone marrow cell cultures and in bone: a specific marker of the differentiated osteoclast that is regulated by calcitonin. , 1995, Endocrinology.

[28]  E. Jimi,et al.  Dexamethasone stimulates osteoclast-like cell formation by inhibiting granulocyte-macrophage colony-stimulating factor production in mouse bone marrow cultures. , 1994, Endocrinology.

[29]  R. Baron,et al.  Macrophage colony‐stimulating factor release and receptor expression in bone cells , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  N. Udagawa,et al.  Preparation and characterization of a mouse osteoclast‐like multinucleated cell population , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  T. Martin,et al.  Modulation of osteoclast differentiation. , 1992, Endocrine reviews.

[32]  J. Korn,et al.  Production of both interleukin‐lα and ß by newborn mouse calvarial cultures , 1990 .

[33]  I. Morita,et al.  Prostaglandins promote osteoclastlike cell formation by a mechanism involving cyclic adenosine 3′,5′‐monophosphate in mouse bone marrow cell cultures , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  T. Martin,et al.  Induction of calcitonin receptors by 1 alpha, 25-dihydroxyvitamin D3 in osteoclast-like multinucleated cells formed from mouse bone marrow cells. , 1988, Endocrinology.

[35]  Sheila J. Jones,et al.  Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. , 1988, Endocrinology.

[36]  G. Mundy,et al.  Effects of human recombinant CSF‐GM and highly purified CSF‐1 on the formation of multinucleated cells with osteoclast characteristics in long‐term bone marrow cultures , 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[38]  C. Ohlsson,et al.  Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. , 1998, Biochemical and biophysical research communications.

[39]  G. Roodman,et al.  Advances in bone biology: the osteoclast. , 1996, Endocrine reviews.

[40]  T. Chambers,et al.  Cellular and molecular mechanisms in the regulation and function of osteoclasts. , 1991, Vitamins and hormones.

[41]  I. Morita,et al.  Prostaglandins promote osteoclast-like cell formation by a mechanism involving cyclic adenosine 3',5'-monophosphate in mouse bone marrow cell cultures. , 1989 .